A new CRISPR-based gene-editing therapy shows promise for treating severe high cholesterol by disabling the ANGPTL3 gene. Early trial results in 15...

Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion by 2032 ......

Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion by 2032 ......

Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension...

Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension...

Originally developed for diabetes, GLP-1 drugs like Ozempic are showing remarkable potential in combating addiction. Emerging research suggests these...

Originally developed for diabetes, GLP-1 drugs like Ozempic are showing remarkable potential in combating addiction. Emerging research suggests these...

SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the...

SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the...

Theralase’s (TSXV:TLT) Ruvidar and Rutherrin show strong potential in treating bladder cancer, solid tumors, and HSV-1.